Minimal hepatic encephalopathy(MHE)is a frequent neurological and psychiatric complication of liver cirrhosis.The precise pathogenesis of MHE is complicated and has yet to be fully elucidated.Studies in cirrhotic patients and experimental animals with MHE have indicated that gut microbiota dysbiosis induces systemic inflammation,hyperammonemia,and endotoxemia,subsequently leading to neuroinammation in the brain via the gut-liver-brain axis.Related mechanisms initiated by gut microbiota dysbiosis have significant roles in MHE pathogenesis.The currently available therapeutic strategies for MHE in clinical practice,including lactulose,rifaximin,probiotics,synbiotics,and fecal microbiota transplantation,exert their effects mainly by modulating gut microbiota dysbiosis.Microbiome therapies for MHE have shown promised efficacy and safety;however,several controversies and challenges regarding their clinical use deserve to be intensively discussed.We have summarized the latest researchndings concerning the roles of gut microbiota dysbiosis in the pathogenesis of MHE via the gut-liver-brain axis as well as the potential mechanisms by which microbiome therapies regulate gut microbiota dysbiosis in MHE patients.
展开▼
